The Role of New Anti-Platelet Agents: Will Prasugrel and …summitmd.com/pdf/pdf/1134_3.DAPT and...
Transcript of The Role of New Anti-Platelet Agents: Will Prasugrel and …summitmd.com/pdf/pdf/1134_3.DAPT and...
Columbia University Medical CenterColumbia University Medical CenterThe Cardiovascular Research FoundationThe Cardiovascular Research Foundation
The Role of New Anti-Platelet Agents:Will Prasugrel and Ticagrelor Change the DES Landscape?
The Role of New Anti-Platelet Agents:Will Prasugrel and Ticagrelor Change the DES Landscape?
Roxana Mehran, MDAssociate Professor of Medicine
Roxana Mehran, MDAssociate Professor of Medicine
Clinical Research Support to Columbia: Clinical Research Support to Columbia: Sanofi/Aventis, BMS, BraccoSanofi/Aventis, BMS, Bracco
Educational/Research Support to CRF: TMC, Educational/Research Support to CRF: TMC, Boston Scientific, Abbott, Medtronic, Cordis, Boston Scientific, Abbott, Medtronic, Cordis, Lilly/Diachi Sankyo, BMS, AZLilly/Diachi Sankyo, BMS, AZ
Consultant/Honoraria: TMC, Sanofi/Aventis, Consultant/Honoraria: TMC, Sanofi/Aventis, Astra Zeneca, Cordis, Therox, Bracco, Astra Zeneca, Cordis, Therox, Bracco, Guerbert, Regado, GileadGuerbert, Regado, Gilead
Clinical Research Support to Columbia: Clinical Research Support to Columbia: Sanofi/Aventis, BMS, BraccoSanofi/Aventis, BMS, Bracco
Educational/Research Support to CRF: TMC, Educational/Research Support to CRF: TMC, Boston Scientific, Abbott, Medtronic, Cordis, Boston Scientific, Abbott, Medtronic, Cordis, Lilly/Diachi Sankyo, BMS, AZLilly/Diachi Sankyo, BMS, AZ
Consultant/Honoraria: TMC, Sanofi/Aventis, Consultant/Honoraria: TMC, Sanofi/Aventis, Astra Zeneca, Cordis, Therox, Bracco, Astra Zeneca, Cordis, Therox, Bracco, Guerbert, Regado, GileadGuerbert, Regado, Gilead
Disclosures: Roxana Mehran
CollagenTXA2
ADPADP
TXA2
ADP PDEPDE
ADP
(Fibrinogen(Fibrinogenreceptor)receptor)
GP IIb/IIIaGP IIb/IIIa
Activation
COX
TiclopidineClopidogrelPrasugrelAZD6140Cangrelor
PRT060128
ASA
Dipyridamole
↑cAMP
Targets for antiplatelet therapies
Thrombin PAR-1
SCH 530348
AbciximabEptifibatide
Tirofiban
Courtesy of BM Scirica, MD.Adapted from Schafer AI.
Am J Med. 1996;101:199-209.cAMP = cyclic adenosine monophosphate, COX = cyclooxygenase, PAR = protease-activated receptor, PDE = phosphodiesterase
2.72.7
6.26.2
3.63.6
3.93.9
0.50.5
1.61.6
5.7 5.7
0.8 0.8
00 3.03.0 5.05.0 8.08.0 1212
STARS (1998)STARS (1998)33
ISAR (1997)ISAR (1997)22
MATTIS (1998)MATTIS (1998)44
Hall (1996)Hall (1996)11
11 Hall P, et al. Hall P, et al. CirculationCirculation. 1996;93:215. 1996;93:215--222.222.22 Schömig A, et al. Schömig A, et al. N Engl J MedN Engl J Med. 1996;335:1084. 1996;335:1084--1089.1089.33 Leon M, et al. Leon M, et al. N Engl J MedN Engl J Med. 1998:339:1665. 1998:339:1665--71.71.44 Urban P, et al. Urban P, et al. CirculationCirculation. 1998 98:2126. 1998 98:2126--2132.2132.5 5 Bertrand M, et al. Bertrand M, et al. Circulation. Circulation. 1998;98:15971998;98:1597--1603. (Events include death, Q1603. (Events include death, Q--wave or nonwave or non--QQ--wave MI).wave MI).
Combination Antiplatelet Therapy Combination Antiplatelet Therapy Reduces Coronary Events after StentingReduces Coronary Events after Stenting
ASA + TiclopidineASA + TiclopidineASA onlyASA onlyASA + WarfarinASA + Warfarin
11.011.0
FANTASTIC (1998)FANTASTIC (1998)55
N =485N =485
5.65.6
8.38.3
N=226N=226
N=517N=517
N=1653N=1653
N=350N=350
P=0.1P=0.1
P=0.01P=0.01
P<0.001P<0.001
Cumulative Event Rate (%)Cumulative Event Rate (%)
P=0.07P=0.07
P=0.37P=0.37
Clopidogrel Trials – ACS/CAD
COMMITCOMMIT(CCS(CCS--2)2)
CAPRIECAPRIELancet 1996Lancet 1996
MI / stroke PAD
2.5 yearsBenefit
selected 2o Prev
STEMI
Acute STEMI Long-term 2o 1 1o preventionUA/NSTEMI PCI
PCIUA/ NSTEMI
+ Benefit + Benefit
1 Year 1 Year
+ Benefit1-3 Years30 Days
+ Benefit
PCI –
ARMYDA-2 Study: Design and Primary End PointPrimary composite of death, MI,
or target vessel revasc. at 30 daysP=.041
4%
0%
2%
4%
6%
8%
10%
12%
14%
600 mg 300 mg
12%
High Loading Dose of
Clopidogrel600 mgPre-PCI
Standard Loading Dose of
Clopidogrel 300 mgPre-PCI
255 patients with stable CAD or NSTEMI prior to PCI
13% received GP IIb/IIIa inhibitors20% received drug-eluting stents
Randomized 4-8 Hours Pre-PCI
ARMYDA-2, Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty.Patti G, et al. Circulation. 2005;111(16):2099-2106.
Study Design, Flow and Compliance25,087 ACS Patients (UA/NSTEMI 70.8%, STEMI 29.2%)
ü Planned Early (<24 h) Invasive Management with intended PCIü Ischemic ECG Δ (80.8%) or ↑cardiac biomarker (42%)
25,087 ACS Patients (UA/NSTEMI 70.8%, STEMI 29.2%)ü Planned Early (<24 h) Invasive Management with intended PCIü Ischemic ECG Δ (80.8%) or ↑cardiac biomarker (42%)
PCI 17,232(70%)
Angio 24,769(99%)
Angio 24,769(99%) No PCI 7,855
(30%)
No Sig. CAD 3,616 CABG 1,809 CAD 2,430
Randomized to receive (2 X 2 factorial):CLOPIDOGREL: Double-dose (600 mg then150 mg/d x 7d then 75 mg/d) vs Standard dose (300 mg
then 75 mg/d)ASA: High Dose (300-325 mg/d) vs Low dose (75-100 mg/d)
Efficacy Outcomes: CV Death, MI or stroke at day 30Stent Thrombosis at day 30
Safety Outcomes: Bleeding (CURRENT defined Major/Severe and TIMI Major)Key Subgroup: PCI v No PCI
Clop in 1st 7d (median) 7d 7 d 2 d 7d
Complete Followup
99.8%
Compliance:
Days
Cum
ulat
ive
Haz
ard
0.0
0.00
40.
008
0.01
2
0 3 6 9 12 15 18 21 24 27 30
Clopidogrel Standard Dose
Clopidogrel Double Dose
42% RRR
HR 0.5895% CI 0.42-0.79
P=0.001
Clopidogrel: Double vs Standard DoseDefinite Stent Thrombosis (Angio confirmed)
Days
Cum
ulat
ive
Haz
ard
0.0
0.01
0.02
0.03
0.04
0 3 6 9 12 15 18 21 24 27 30
Clopidogrel: Double vs Standard Dose Primary Outcome: PCI Patients
Clopidogrel Standard
Clopidogrel Double
HR 0.8595% CI 0.74-0.99
P=0.036
15% RRR
CV Death, MI or Stroke
Definite Stent Thrombosis in 4 Groups (Angiographically Proven)
Days
Cum
ulat
ive
Haz
ard
0.0
0.00
40.
008
0.01
2
0 3 6 9 12 15 18 21 24 27 30
C Standard, A Low
C Standard, A High
C Double, A Low
C Double, A High
Standard Clop
Double Clop HR P
PIntn
High ASA 1.2 0.6 0.49 0.003
Low ASA 1.2 0.8 0.6 0.058 0.35
0
5
10
15
0 30 60 90 180 270 360 450
HR 0.81(0.73-0.90)P=0.0004P=0.0004
Prasugrel
Clopidogrel
HR 0.80P=0.0003P=0.0003
HR 0.77P=0.0001P=0.0001
Days
Prim
ary
Endp
oint
(%)
12.1(781)
9.9 (643)
NNT= 46
ITT= 13,608ITT= 13,608 LTFU = 14 (0.1%)LTFU = 14 (0.1%)
Primary Endpoint CV Death,MI,Stroke
Stent Thrombosis(ARC Definite + Probable)
0
1
2
3
0 30 60 90 180 270 360 450
HR 0.48P <0.0001P <0.0001
Prasugrel
Clopidogrel 2.4(142)
NNT= 77
1.1 (68)
Days
Endp
oint
(%)
Any Stent at Index PCIAny Stent at Index PCIN= 12,844N= 12,844
Death Following STDeath Following ST
Mortality During Follow up (%) Post-Stent Thrombosis
STENT ANALYSIS
N=210 N=12634
HR 13.1 (9.8 – 17.5) P<0.0001
% o
f Sub
ject
s
0
5
10
15
0 30 60 90 180 270 360 450
HR 0.81(0.73-0.90)P=0.0004P=0.0004
Prasugrel
Clopidogrel
Days
Endp
oint
(%)
12.1
9.9
HR 1.32(1.03-1.68)
P=0.03P=0.03
Prasugrel
Clopidogrel1.82.4
138events
35events
CV Death / MI / Stroke
TIMI Major NonCABG Bleeds
NNT = 46
NNH = 167
Balance of Efficacy and Safety
Ticagrelor (AZD 6140): an oral reversible P2Y12 antagonist
Ticagrelor is a cyclo-pentyl-triazolo-pyrimidine (CPTP)
OH
OH
O
OH
N
F
S
NH
NN
NN
F
• Direct acting – Not a prodrug; does not require metabolic activation– Rapid onset of inhibitory effect on the P2Y12 receptor– Greater inhibition of platelet aggregation than clopidogrel
• Reversibly bound– Degree of inhibition reflects plasma concentration– Faster offset of effect than clopidogrel – Functional recovery of all circulating platelets
PLATO study design
Primary endpoint: CV death + MI + Stroke Primary safety endpint: Total major bleeding
6–12-month exposure
ClopidogrelIf pre-treated, no additional loading dose;if naive, standard 300 mg loading dose,
then 75 mg qd maintenance;(additional 300 mg allowed pre PCI)
Ticagrelor180 mg loading dose, then
90 mg bid maintenance;(additional 90 mg pre-PCI)
NSTE-ACS (moderate-to-high risk) STEMI (if primary PCI)Clopidogrel-treated or -naive;
randomised within 24 hours of index event (N=18,624)
PCI = percutaneous coronary intervention; ASA = acetylsalicylic acid; CV = cardiovascular; TIA = transient ischaemic attack
K-M estimate of time to first primary efficacy event (composite of CV death, MI or stroke)
No. at risk
ClopidogrelTicagrelor
9,2919,333
8,5218,628
8,3628,460
8,124
Days after randomisation
6,7436,743
5,0965,161
4,0474,147
0 60 120 180 240 300 360
121110
9876543210
13
Cum
ulat
ive
inci
denc
e (%
)9.8
11.7
8,219
HR 0.84 (95% CI 0.77–0.92), p=0.0003
Clopidogrel
Ticagrelor
K-M = Kaplan-Meier; HR = hazard ratio; CI = confidence interval
No. at risk
Clopidogrel
Ticagrelor
9,291
9,333
8,560
8,678
8,405
8,520
8,177
Days after randomisation
6,703
6,796
5,136
5,210
4,109
4,191
0 60 120 180 240 300 360
6
5
4
3
2
1
0
7
Cum
ulat
ive
inci
denc
e (%
)
Clopidogrel
Ticagrelor
5.8
6.9
8,279
HR 0.84 (95% CI 0.75–0.95), p=0.005
0 60 120 180 240 300 360
6
4
3
2
1
0
Clopidogrel
Ticagrelor
4.0
5.1
HR 0.79 (95% CI 0.69–0.91), p=0.001
7
5
9,291
9,333
8,865
8,294
8,780
8,822
8,589
Days after randomisation
7079
7119
5,441
5,482
4,364
4,4198,626
Myocardial infarction Cardiovascular death
Cum
ulat
ive
inci
denc
e (%
)
Secondary efficacy endpoints over time
Stent thrombosis
Ticagrelor(n=5,640)
Clopidogrel(n=5,649)
HR (95% CI) p value
Stent thrombosis, n (%)
Definite
Probable or definite
Possible, probable, definite
71 (1.3)
118 (2.1)
155 (2.8)
106 (1.9)
158 (2.8)
202 (3.6)
0.67 (0.50–0.91)
0.75 (0.59–0.95)
0.77 (0.62–0.95)
0.009
0.02
0.01
(evaluated in patients with any stent during the study)
*Time-at-risk is calculated from first stent insertion in the study or date of randomisation
Time to major bleeding – primary safety event
No. at risk
ClopidogrelTicagrelor
9,1869,235
7,3057,246
6,9306,826
6,670
Days from first IP dose
5,2095,129
3,8413,783
3,4793,433
0 60 120 180 240 300 360
10
5
0
15
Clopidogrel
Ticagrelor11.2011.58
6,545
HR 1.04 (95% CI 0.95–1.13), p=0.434K-M
est
imat
ed ra
te (%
per
yea
r)
Safety of New DAPT Regimens3 Active Controlled Trials (vs Standard Clop) 3 Active Controlled Trials (vs Standard Clop)
2.0%3.8% 3.8% 3.2%
7.9%
2.5%
5.0% 4.5%
13.4%
7.4%
0%
3%
6%
9%
12%
15%
CURRENT TRITON PLATO TRITONCABG
PLATOCABG
Sig
nif
ican
t b
leed
ing
(%
) ASA + ClopidogrelNew Regimen
P=0.001P=0.001
N=25,087N=25,08711--month FUmonth FUCURRENT CURRENT major bleedmajor bleed
NEJM 2009NEJM 2009
P<0.001P<0.001 P=0.32P=0.32
N=13,608N=13,6081515--month FUmonth FU
TIMI major+minor TIMI major+minor bleedbleed
NEJM 2007NEJM 2007
N=18,864N=18,8641212--month FUmonth FU
PLATOPLATOMajor bleedMajor bleedNEJM 2009NEJM 2009
TIMI major+minor TIMI major+minor bleedbleed
NEJM 2007NEJM 2007
PLATOPLATOMajor bleedMajor bleedNEJM 2009NEJM 2009
P=0.03P=0.03P=0.002P=0.002
NonNon--CABG related bleedingCABG related bleeding
Efficacy of New DAPT Rx in ACS3 Active Controlled Trials (vs Standard Clop) 3 Active Controlled Trials (vs Standard Clop)
4.4%
12.1% 11.7%
2.3% 2.4% 2.8%4.2%
9.9% 9.8%
1.6% 1.1%2.1%
0%
3%
6%
9%
12%
15%
CURRENT TRITON PLATO CURR. ST TRITON ST PLATO ST
Sig
nif
ica
nt
Ev
en
ts (
%) ASA + Clopidogrel
New Regimen
P=0.37P=0.37
N=25,087N=25,08711--month FUmonth FU
D/MI/CVAD/MI/CVAESC 2009ESC 2009
P=0.02P=0.02
N=13,608N=13,6081515--month FUmonth FU
D/MI/CVAD/MI/CVANEJM 2007NEJM 2007
Def/ProbDef/ProbESC 2009ESC 2009
Def/ProbDef/ProbNEJM 2007NEJM 2007
Def/ProbDef/ProbNEJM 2009NEJM 2009
P=0.0003P=0.0003
P=0.002P=0.002 P<0.001P<0.001
P<0.001P<0.001
N=18,864N=18,86411-- Year FUYear FUD/MI/CVAD/MI/CVANEJM 2009NEJM 2009
Efficacy of New DAPT Rx: ACS+PCI3 Active Controlled Trials (vs Standard Clop) 3 Active Controlled Trials (vs Standard Clop)
4.5%
12.1%10.7%
2.3% 2.4% 2.3%3.9%
9.9%9.0%
1.6% 1.1% 1.7%
0%
3%
6%
9%
12%
15%
CURRENT TRITON PLATO CURR. ST TRITON ST PLATO ST
Sig
nif
ican
t E
ven
ts (
%) ASA + Clopidogrel
New Regimen
P=0.04P=0.04
N=17,232N=17,23211--month FUmonth FU
D/MI/CVAD/MI/CVAESC 2009ESC 2009
P<0.001P<0.001 P=0.01P=0.01
N=13,608N=13,6081515--month FUmonth FU
D/MI/CVAD/MI/CVANEJM 2007NEJM 2007
Def/ProbDef/ProbESC 2009ESC 2009
Def/ProbDef/ProbNEJM 2007NEJM 2007
Def/ProbDef/ProbNEJM 2009NEJM 2009
P=0.003P=0.003
P=0.002P=0.002
P<0.001P<0.001
N=11,289N=11,28911--year FUyear FUD/MI/CVAD/MI/CVATCT 2009TCT 2009
How will these results change the landscape?
ischemic ischemic events events bleedingbleedingThrombosis Bleeding
25
Stent thrombosis: Past and present trial results
02468
1012141618
0-30d
CoumadinHigh-pressure
balloons and Ticlid®
SES BMS PES BMS
0-30d 30d-1y 1y-4y
30 day resultsBMS Trials 1991-1997
4 year results definite and probable ARCPooled DES vs BMS Trials 2002-2006
16%
0.6%
Schatz et al. Circulation.1991;83:148; Fischman et al. N Engl J Med. 1994;331496; Colombo et al. Circulation.1995;91:1676; Schömig et al.Circulation.1994,90:2716; Leon et al. N Engl J Med. 1998;339:1665; Mauri et al. N Engl J Med. 2007;356:1020-9.
26Cutlip et al. Circulation 2004; 110: 1226–1230.
18.3%
2.3%1.3% 1.5% 1.4%
5.6%7.0%
5.7%6.7%
12.4%
0%
5%
10%
15%
20%
25%
Year 1 Year 2 Year 3 Year 4 Year 5
Haz
ard
Rat
e
Target Lesion EventNon-target Lesion Event
bbbbbbbbbbb
Non Target Lesion Events outnumber stent Non Target Lesion Events outnumber stent specific outcomes in long term follow upspecific outcomes in long term follow upHCRI database N=6186 with complete 5y follow upHCRI database N=6186 with complete 5y follow up
27
Stent thrombosis accounts for a minority of Stent thrombosis accounts for a minority of clinical eventsclinical events
SESSES BMSBMS PESPES BMSBMS
DeathDeath 57 (6.7%)57 (6.7%) 45 (5.3%)45 (5.3%) 86 (6.1%)86 (6.1%) 92 (6.6%)92 (6.6%)
ST DeathST Death 4 (0.5%)4 (0.5%) 5 (0.6%)5 (0.6%) 7 (0.5%)7 (0.5%) 5 (0.4%)5 (0.4%)
ST death/ST death/total deathtotal death
7%7% 11%11% 8%8% 6 %6 %
ST represents less about 10% of mortality, and a smaller proportion of death/MI composite.
Clinical endpoints may not distinguish differences in ST
Mauri, L. N Engl J Med 2007;356:1020-9.
Bleeding and Mortality
Major Bleeding
TransfusionHypotension
Ischemia Stent Thrombosis Inflammation
Mortality
Cessation of ASA/Clop
Bhatt DL. In Braunwald EB, Harrison’s Online. 2005.
HR [95% CI] P-valueAttributable
DeathsRisk Factor
TimeTime--updated covariate adjusted Cox model updated covariate adjusted Cox model relating 30relating 30--day events to 30day events to 30--day mortalityday mortality
-- Complete modelComplete model in 3,124 pts with successfully implanted stents in 3,124 pts with successfully implanted stents --
Hazard Ratio [95% CI]Hazard Ratio [95% CI]0.01 0.1 1 10 100
CC--statistic = 0.87. statistic = 0.87. Attributable deaths = N deaths among pts Attributable deaths = N deaths among pts with the time updated event (attribute) X (adj. HR with the time updated event (attribute) X (adj. HR –– 1)/adj. HR1)/adj. HR
*8.3% of 54 total deaths*8.3% of 54 total deaths**28.0% of 54 total deaths**28.0% of 54 total deaths
Major bleeding(non CABG)Incidence 195 (6.2%)18 deaths with event
6.22[3.33, 11.60]
<0.001 15.1** 15.1** [12.6, 16.4][12.6, 16.4]
Stent thrombosis(definite)Incidence 57 (1.8%)5 deaths with event
10.62[3.96, 28.48]
<0.001 4.5* 4.5* [3.7, 4.8][3.7, 4.8]
Definitions of Major/Severe Bleeding Definitions of Major/Severe Bleeding in Randomized Controlled Clinical Trialsin Randomized Controlled Clinical Trials
PLATOACUITYHORIZONSSTEEPLECUREOASIS-5
ESSENCEREPLACE-2TIMI phase II
TIMI phase IGUSTOType of bleeding
+++++++++Intracranial/intracerebral
++++++---Intraocular
-+++++---Retroperitoneal
+-++----+Bleeding causing hemodynamic compromise
+-----++-Cardiac tamponade
++++-----Bleeding requiring surgical intervention
-+-------Hematoma >5cm at the puncture site
≥4≥1≥1≥2≥2≥2≥1≥1≥1Transfusion, units
≥5.0≥3.0≥3.0-≥3.0≥3.0≥3.0≥5.0*-Decrease in Hgb with overt bleeding, g/dL
-≥4.0-≥5.0-≥4.0---Decrease in Hgb withoutovert bleeding, g/dL
*Or decrease in Hct ≥15%
Type of BleedType of Bleed HR (95% CI)HR (95% CI) PP--valuevalue
Attributable Attributable deaths deaths
within 1 yrwithin 1 yr
TIMI major bleedTIMI major bleed 4.85 (3.564.85 (3.56--6.60)6.60) <0.001<0.001 5353
ACUITY major (non TIMI ACUITY major (non TIMI major) bleed with major) bleed with transfusion*transfusion*
2.98 (2.102.98 (2.10--4.24)4.24) <0.001<0.001 4040
ACUITY major (non TIMI ACUITY major (non TIMI major) bleed without major) bleed without transfusion*transfusion*
1.79 (1.091.79 (1.09--2.93)2.93) 0.020.02 1717
Hematoma ≥5 cm onlyHematoma ≥5 cm only 1.30 (0.581.30 (0.58--2.92)2.92) 0.530.53 66
Influence of Bleeding Severity within 30 Days Influence of Bleeding Severity within 30 Days After PCI on the Risk of Death Over 1 YearAfter PCI on the Risk of Death Over 1 Year
Baseline covariateBaseline covariate--adjusted timeadjusted time--updated Cox multivariable modelupdated Cox multivariable model
HR (HR (95%CI95%CI))
* Excluding hematomas if the only criteria* Excluding hematomas if the only criteriaEach patient is represented only once according to their most severe bleedEach patient is represented only once according to their most severe bleed
D 5mkM ADP Platelet Aggregation
Patient Numbers112
32
0
48
64
16
< 0
80
96
(0,10)(11,20)
(21,30)(31,40)
(41,50)(51,60)
(61,70)(71,80)
(81,90)(91,100)
>100
D 5mkM ADP Platelet Aggregation
Patient Numbers112
32
0
48
64
16
< 0
80
96
(0,10)(11,20)
(21,30)(31,40)
(41,50)(51,60)
(61,70)(71,80)
(81,90)(91,100)
>100
Change in Platelet Aggregation between Pre- and Post-Clopidogrel Time Points: Distribution
Mean 41.9%
Hypo
(-2 SD)Hyper
(+2 SD)
From Serebruany, et al. JACC 2005;45:246-251
Impact of clopidogrel hyporesponsiveness Impact of clopidogrel hyporesponsiveness after stents: after stents: 683 pts with ACS after BMS or DES were 683 pts with ACS after BMS or DES were tested by the VerifyNow P2Y12 assay within 24 hrs after tested by the VerifyNow P2Y12 assay within 24 hrs after
600 mg clopidogrel load. By ROC, pts with PRU ≥240 600 mg clopidogrel load. By ROC, pts with PRU ≥240 defined as nonresponders. defined as nonresponders.
MarcucciMarcucci R et al. Circulation 2009;119:237R et al. Circulation 2009;119:237--242242
P=0.01P=0.01 P=0.23P=0.23P=0.006P=0.006P=0.03P=0.03
Impact of clopidogrel hyporesponsiveness Impact of clopidogrel hyporesponsiveness after DES: after DES: 804 pts after PES or SES were tested by LTA 804 pts after PES or SES were tested by LTA
1212--18 hrs after 600 mg clopidogrel load. Pts with platelet 18 hrs after 600 mg clopidogrel load. Pts with platelet aggregation by 10 umol ADP ≥90th percentile of controls aggregation by 10 umol ADP ≥90th percentile of controls
(70%) were defined as non responders. (70%) were defined as non responders.
Buonamici P et al. JACC 2007;49:2312Buonamici P et al. JACC 2007;49:2312––77
P<0.001P<0.001P<0.001P<0.001 P<0.001P<0.001
P=0.61P=0.61
N=2N=9
Impact of clopidogrel Impact of clopidogrel hyporesponsiveness after DEShyporesponsiveness after DES
Price MJ et al. Price MJ et al. EHJEHJ 2008;29:9922008;29:992––10001000
Clopidogrel responsiveness in loaded pts was assessed in Clopidogrel responsiveness in loaded pts was assessed in 380 pts receiving SES by the Accumetrics VerifyNow 380 pts receiving SES by the Accumetrics VerifyNow P2Y12P2Y12assay. assay. Hyporesponsiveness was defined as postHyporesponsiveness was defined as post--treatment treatment reactivity reactivity PRUPRU ≥235 (~ the upper tertile) by ROC analysis to ≥235 (~ the upper tertile) by ROC analysis to
optimize prediction of 6 month MACE. optimize prediction of 6 month MACE.
P=0.04
P=0.008P=0.004
P=0.04
N=5
ADAPTADAPT--DESDESAAssessment of ssessment of DDual ual AAntintiPPlateletlatelet TTherapy with herapy with DDrugrug--EEluting luting SStentstents
11,000 11,000 –– 15,000 pts15,000 pts1010--15 sites in US, Germany, Italy15 sites in US, Germany, Italy
Clinical FU ≥2 yrs (5 yrs max)Clinical FU ≥2 yrs (5 yrs max)Angio core lab assessment all STs w/1:3 matching controlsAngio core lab assessment all STs w/1:3 matching controls
Assessment of platelet function: Assessment of platelet function: Accumetrics VerifyNow Aspirin, VerifyNow Accumetrics VerifyNow Aspirin, VerifyNow P2Y12P2Y12, and VerifyNow IIb/IIIa assays (results blinded to investigators), and VerifyNow IIb/IIIa assays (results blinded to investigators)
Aspirin: Aspirin: ≥300 mg oral ≥6 hrs or 324 mg chewed or 250 mg IV ≥30 mins prior to PCIClopidogrel: Clopidogrel: Assess ≥6’ after 600 mg or ≥12’ after 300 mg or ≥5d after 75 mg qd
GP IIb/IIIa inhibitor: GP IIb/IIIa inhibitor: Optional per standard of care, but washout required
PCI with non investigational DESPCI with non investigational DES(IVUS/VH substudy; n=3000)(IVUS/VH substudy; n=3000)
ACC/AHA/SCAI 2005 Guideline Update for PCIOral Anti-platelet Adjunctive Therapies
In patients in whom subacute thrombosis may be catastrophic or lethal (unprotected left main, bifurcating left main, or last patent coronary vessel), platelet aggregation studies may be considered and the dose of clopidogrel increased to 150 mg per day if less than 50% inhibition of platelet aggregation is demonstrated.
I IIa IIb III
C
Adapted from Smith SC Jr, et al. Available at: www.acc.org/clinical/guidelines/percutaneous/update/index_rev.pdf
“Standard Therapy”clopidogrel 75mg +placebo/day
“Standard Therapy”clopidogrel 75mg +placebo/day
“Tailored Therapy”clopidogrel 150-mg/day
Successful PCI with DES without major complication or GPIIb/IIIa use
Post-PCI VerifyNow P2Y12 Assay (PRU) 12-24 hours post-PCI
PRU ≥ 230?
Non-Responder
Clinical Follow-up And VerifyNow Assessment at 30 days, 6 months
Primary Endpt: 6 month CV Death, Non-Fatal MI, ARC Def/Prob Stent Thrombosis
Yes No
N ~ 6600
N = 1100 N = 583
Responder
A B C
Random Selection
N = 1100
G R A V T A S
Coordinating Center: Scripps Advanced Clinical TrialsStudy PI: Matthew J. Price, MD
ACC/AHA/SCAI 2005 Guideline Update for PCIOral Antiplatelet Adjunctive Therapies
In patients who have undergone PCI, clopidogrel 75 mg daily should be given for at least 1 month after bare-metal stent implantation (unless the patient is at increased risk of bleeding; then it should be given for a minimum of 2 weeks), 3 months after sirolimus stent implantation, and 6 months after paclitaxel stent implantation, and ideally up to 12 months in patients who are not at high risk of bleeding.
I IIa IIb III
B
Adapted from Smith SC Jr, et al. Available at: www.acc.org/clinical/guidelines/percutaneous/update/index_rev.pdf
Clopidogrel
Clopidogrel for >1-year?
41
DAPT Study DesignDAPT Study Design
4141
50% of patients continue onDual Antiplatelet Therapy
18 mos.12 mos.
50% of patients receive aspirin + placebo
Total 33 month patient evaluation including additional 3-month follow-up
All patients onaspirin +open-label
thienopyridinetherapy for 12 months
DES n =
15,245BMS n =
5,400 1:1 Randomization at month 12
MI, Bleeding and AllMI, Bleeding and All--Cause MortalityCause Mortality
TrialTrial MIMI Major bleed*Major bleed* Death (time)Death (time)
OASISOASIS--5 (n=20,078)5 (n=20,078) 6 months6 months-- EnoxaparinEnoxaparin 4.1%4.1% 5.0%5.0% 6.5%6.5%-- FondaparinuxFondaparinux 3.9%3.9% 3.1%3.1% 5.8%5.8%
HORIZONS (n=3,602)HORIZONS (n=3,602) 1 year1 year-- UFH/GPIUFH/GPI 1.8%1.8% 10.8%10.8% 4.8%4.8%-- BivalirudinBivalirudin 1.8%1.8% 6.8%6.8% 3.5%3.5%
PLATO (n=18,624)PLATO (n=18,624) 1 year1 year-- ClopidogrelClopidogrel 6.9%6.9% 11.2%11.2% 5.9%5.9%-- TicagrelorTicagrelor 5.8%5.8% 11.6%11.6% 4.5%4.5%
Large RCTs Large RCTs withwith significant reductions in deathsignificant reductions in death
*TIMI major + minor or protocol major*TIMI major + minor or protocol major
-- ↓↓ ↓↓
-- ↓↓↓↓ ↓↓
↓↓ -- ↓↓
Stone, GW NEJM 2010
TrialTrial MIMI Major bleed*Major bleed* Death (time)Death (time)CHARISMA (n=15,603)CHARISMA (n=15,603) 28 28 mosmos
-- PlaceboPlacebo 2.0%2.0% 1.3%1.3% 4.8%4.8%-- ClopidogrelClopidogrel 1.9%1.9% 1.7%1.7% 4.8%4.8%
CURRENT (n=25,807)CURRENT (n=25,807) 30 days (CV)30 days (CV)-- LD ClopidogrelLD Clopidogrel 2.2%2.2% 2.0%2.0% 2.2%2.2%-- HD ClopidogrelHD Clopidogrel 1.9%1.9% 2.5%2.5% 2.1%2.1%
SYNERGY (n=10,027)SYNERGY (n=10,027) 1 year1 year-- UFHUFH 12.7%12.7% 7.6%7.6% 7.3%7.3%-- Enoxaparin Enoxaparin 11.7%11.7% 9.1%9.1% 7.7%7.7%
REPLACEREPLACE--2 (n=6,010) 2 (n=6,010) 1 year1 year-- UFH/GPIUFH/GPI 6.2%6.2% 4.1%4.1% 1.4%1.4%-- BivalirudinBivalirudin 7.0%7.0% 2.4%2.4% 1.0%1.0%
ACUITY (n=9,215)ACUITY (n=9,215) 1 year1 year-- UFH/GPIUFH/GPI 4.9%4.9% 11.8%11.8% 3.9%3.9%-- BivalirudinBivalirudin 5.4%5.4% 9.1%9.1% 3.8%3.8%
CURE (N=12,562)CURE (N=12,562) 1 year1 year-- PlaceboPlacebo 6.7%6.7% 2.7%2.7% 6.2%6.2%-- ClopidogrelClopidogrel 5.2%5.2% 3.7%3.7% 5.8%5.8%
TRITON (n=13,608)TRITON (n=13,608) 15 15 mosmos-- ClopidogrelClopidogrel 9.5%9.5% 3.8%3.8% 3.2%3.2%-- PrasugrelPrasugrel 7.3%7.3% 5.0%5.0% 3.0%3.0%
MI, Bleeding and AllMI, Bleeding and All--Cause MortalityCause MortalityLarge RCTs Large RCTs withoutwithout significant reductions in deathsignificant reductions in death
-- -- --
↓↓ ↑↑ --
-- --↑↑ --
↓↓ ↑↑ --
--↓↓ ↑↑ --
--↑↑ ↓↓ --
--↑↑ ↓↓ --
Stone, GW NEJM 2010
ConclusionsvvPharmacologic treatment of patients Pharmacologic treatment of patients
undergoing PCI has improved over the years undergoing PCI has improved over the years to decrease ischemic and bleeding to decrease ischemic and bleeding complicationscomplications
vvAs most drugs which ↓ ischemia also ↑ As most drugs which ↓ ischemia also ↑ bleeding, the offsetting impact of adverse bleeding, the offsetting impact of adverse ischemic and hemorrhagic events must be ischemic and hemorrhagic events must be carefully examined carefully examined
vvThe net balance of ischemia and bleeding The net balance of ischemia and bleeding should be strongly considered when should be strongly considered when choosing APT for individual pts in an attempt choosing APT for individual pts in an attempt to minimize complicationsto minimize complications